Safety and efficacy of intralesional bleomycin for keloids and hypertrophic scars: A systematic review and meta‐analysis
Journal of Cosmetic Dermatology · 2024
DOI: 10.1111/jocd.16447 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von Shun Jie You und 6 weiteren Autor:innen. Beteiligte Einrichtung: Plastic and Reconstructive Surgery & Burns, Affiliated Hospital of North Sichuan Medical College, Sichuan, Nanchong, China. Hauptthemen laut MEDLINE: Bleomycin, Cicatrix, Hypertrophic, Keloid. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Affiliated Hospital of North Sichuan Medical College.
Abstract (Originalsprache)
Background
Bleomycin, originally an antitumor drug, was explored as a pathological scar treatment in the mid‐1990s. However, its efficacy and safety profile varies among individuals.
Aims
This study aimed to assess topical bleomycin's efficacy and safety in treating hypertrophic scars and keloids.
Methods
We reviewed randomized controlled trials (RCTs) and controlled clinical trials (CCTs) published in English, comparing intralesional bleomycin to placebos or common intralesional scar treatments. Primary outcomes included percentage change in scar improvement, pigmentation, recurrence, atrophy, pain, telangiectasia, ulceration, patient self‐assessment, and observer assessment (>50%).
Results
Six trials met the criteria. Bleomycin significantly improved scar reduction compared to triamcinolone ( p < 0.05). There was no significant difference in pigmentation ( p = 0.05) and recurrence ( p = 0.21) compared to other treatments. In terms of safety, bleomycin caused less skin atrophy ( p < 0.01) and telangiectasia ( p < 0.01) but more pain ( p = 0.03) than other treatments.
Conclusions
Bleomycin was more effective than TAC, 5‐FU, or TAC combined with 5‐FU for treating keloids and hypertrophic scars with lower skin atrophy and telangiectasia risks. However, it may cause more pain than 5‐FU or TAC. Further comprehensive studies, including RCTs, are required for objective analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Plastic and Reconstructive Surgery & Burns, Affiliated Hospital of North Sichuan Medical College, Sichuan, Nanchong, China.
- Dermatology, Affiliated Hospital of North Sichuan Medical College, Sichuan, Nanchong, China.
- Department of Vascular Surgery Dazhou, Sichuan, Nanchong, China.
- Genetics and Prenatal Diagnosis Center, Affiliated Hospital of North Sichuan Medical College, Sichuan, Nanchong, China.
ORCID-Profile: Shun Jie You, Si Li, Chen Ming Hu, Fang Yu Zhong, Shi Han Gan, Yan Cai, Xiao Yan Xiang
Förderung
- Affiliated Hospital of North Sichuan Medical College
Zitieren
APA
You, S. J., Li, S., Hu, C. M., Zhong, F. Y., Gan, S. H., Cai, Y., & Xiang, X. Y. (2024). Safety and efficacy of intralesional bleomycin for keloids and hypertrophic scars: A systematic review and meta‐analysis. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16447
Vancouver
You SJ, Li S, Hu CM, Zhong FY, Gan SH, Cai Y, et al. Safety and efficacy of intralesional bleomycin for keloids and hypertrophic scars: A systematic review and meta‐analysis. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.16447
BibTeX
@article{You2024,
author = {You, Shun Jie and Li, Si and Hu, Chen Ming and Zhong, Fang Yu and Gan, Shi Han and Cai, Yan and Xiang, Xiao Yan},
title = {Safety and efficacy of intralesional bleomycin for keloids and hypertrophic scars: A systematic review and meta‐analysis},
journal = {Journal of Cosmetic Dermatology},
year = {2024},
doi = {10.1111/jocd.16447}
}
EUVIMED